PharmFilm was developed to provide meaningful clinical and therapeutic differentiation to better meet the needs of patients, caregivers, and physicians. Similar in size and thickness to a stamp, PharmFilm can provide potentially faster onset of action, improved dosing accuracy, and can be administered without water – attributes that can significantly improve compliance and adherence. Failure to take medication as prescribed takes a tremendous toll, especially on those with complex diseases to manage.
Here’s more information about PharmFilm
Potential advantages of the PharmFilm technology platform
| For Commercial Partners | For Patients | For Physicians |
|---|---|---|
| Worldwide leader in oral film drug delivery and manufacturing
Recognized partner of choice Extensive global IP protection Customizable delivery routes for tailored PK profiles (buccal, sublingual, or lingual options) |
Simplified, independent, and discrete administration for patients and caregivers
Potential faster onset of action Improved dosing accuracy, especially for patients with physical or psychological barriers to other delivery systems Potential reduction of adverse GI events Suitable for those suffering from dysphagia Stable, durable, portable, and quick-dissolving Can be administered without water Customizable taste profiles |
Ensures full-dose delivery
Treatment option that offers patient-friendly administration Ability to titrate through starter packs Potential direct delivery to bloodstream
|
Potential advantages of the PharmFilm technology platform
For Commercial Partners
Worldwide leader in oral film drug delivery and manufacturing
Recognized partner of choice
Extensive global IP protection
Customizable delivery routes for tailored PK profiles (buccal, sublingual, or lingual options)
For Patients
Simplified, independent, and discrete administration
Potential faster onset of action
Improved dosing accuracy, especially for patients with physical or psychological barriers to other delivery systems
Potential reduction of adverse GI events
Suitable for those suffering from dysphagia
Stable, durable, portable, and quick-dissolving
Can be administered without water
Customizable taste profiles
Improved patient and caregiver administration experience
For Physicians
Ensures full-dose delivery
Treatment option that offers patient-friendly administration
Ability to titrate through starter packs
Potential direct delivery to bloodstream
– reduced GI side effects
– lower dose exposures with comparable PK profiles
The science behind PharmFilm
| How does PharmFilm work? | Kinetics: Tmax & Cmax | Oral cavity absorption |
|---|---|---|
| Polymers are used as film formers to hold API and excipients in place
Patented techniques are used to ensure the API is uniformly distributed throughout the film Aquestive utilizes the proprietary technology features of PharmFilm along with pH modifiers and permeation enhancers to achieve target absorption. |
Deep understanding of oral mucosa allows for tailored absorption profiles
Novel use of permeation enhancers, stabilizers, and polymer blends ensures consistent and reproducible delivery of active ingredients Film designs are customized to maximize transcellular and/or intercellular transport across the buccal mucosa. |
Upon application to the mucosa, PharmFilm begins to dissolve based on the compositional profile created during formulation
APIs or proteins are released at a rate determined by the proprietary compositional profile. |
How does PharmFilm work?
Polymers are used as film formers to hold API and excipients in place
Patented techniques are used to ensure the API is uniformly distributed throughout the film
Aquestive utilizes the proprietary technology features of PharmFilm (unidirectional release, dissolution rate, direct tissue exposure) along with known pH modifiers and permeation enhancers to protect complex molecules from enzymatic degradation and drive absorption through the buccal mucosa.
Kinetics: Tmax & Cmax
Deep understanding of oral mucosa allows for tailored absorption profiles
Proprietary permeation enhancers, stabilizers, and polymer blends ensure effective, reproducible, and non irritating delivery of active ingredients
Film designs are customized to maximize transcellular and/or intercellular transport across the buccal mucosa.
Oral cavity absorption
Upon application to the mucosa, the polymers and excipients begin to dissolve based on the proprietary compositional profile created during formulation
API is released at a rate determined by the proprietary compositional profile created by Aquestive
Controlling the release rate allows Aquestive to vary the kinetics created by various APIs or proteins
Sustained or quick release have a direct impact on Tmax and Cmax and bioavailabilty enhancements
PharmFilm has three distinct delivery/absorption sites
| Buccal delivery | Sublingual delivery | Lingual delivery |
|---|---|---|
| Controlled release to optimize absorption
Increased retention time at site of absorption Controlled microenvironment for optimized absorption Improved bioavailability |
Rapid disintegration and release to sublingual mucosa
Faster onset via direct delivery to the systemic circulation Potential to improve bioavailability of APIs subject to hepatic degradation Suite of GRAS permeation enhancers to optimize delivery |
Provides rapid disintegration
API released for GI absorption Bioequivalent to tablet/ capsule formulations Variety of taste masking strategies available |
Buccal delivery
Controlled release to optimize absorption
Increased retention time at site of absorption
Controlled microenvironment for optimized absorption
Improved bioavailability
Sublingual delivery
Rapid disintegration and release to sublingual mucosa
Faster onset via direct delivery to the systemic circulation
Potential to improve bioavailability of APIs subject to hepatic degradation
Suite of GRAS permeation enhancers to optimize delivery
Lingual delivery
Provides rapid disintegration
API released for GI absorption
Bioequivalent to tablet/ capsule formulations
Variety of taste masking strategies available
Manufacturing
Aquestive supplies more than 95% of the world’s oral films and we have the capability to produce more than 1 billion commercial doses a year.
Regulatory success
We are proud of our legacy of regulatory firsts, including the first FDA film approvals for lingual, sublingual, and combination drug delivery. The path is set for our innovative therapies to continue altering the landscape of treatment options and improving the lives of patients worldwide.
To learn how PharmFilm can transform
your product or to request a sample,
please complete the following form:
Latest comments
Sorry, the comment form is closed at this time.